热门出版物 - 学术资源搜索

引用“”的文章Cytokine release syndrome

标题/作者	年份
The pathogenesis and treatment of theCytokine Storm'in COVID-19 Q Ye, B Wang, J Mao Journal of infection 80 (6), 607-613	2020
A guide to cancer immunotherapy: from T cell basic science to clinical practice AD Waldman, JM Fritz, MJ Lenardo Nature Reviews Immunology 20 (11), 651-668	2020
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality C Zhang, Z Wu, JW Li, H Zhao, GQ Wang International journal of antimicrobial agents 55 (5), 105954	2020
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China W Zhang, Y Zhao, F Zhang, Q Wang, T Li, Z Liu, J Wang, Y Qin, X Zhang, ... Clinical immunology 214, 108393	2020
COVID-19: what has been learned and to be learned about the novel coronavirus disease Y Yi, PNP Lagniton, S Ye, E Li, RH Xu International journal of biological sciences 16 (10), 1753	2020
COVID-19: immunopathogenesis and Immunotherapeutics L Yang, S Liu, J Liu, Z Zhang, X Wan, B Huang, Y Chen, Y Zhang Signal transduction and targeted therapy 5 (1), 128	2020
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? B Liu, M Li, Z Zhou, X Guan, Y Xiang Journal of autoimmunity 111, 102452	2020
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression D Zhou, SM Dai, Q Tong Journal of Antimicrobial Chemotherapy 75 (7), 1667-1670	2020
Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts J Wang, M Jiang, X Chen, LJ Montaner Journal of Leucocyte Biology 108 (1), 17-41	2020
COVID-19: Immunology and treatment options S Felsenstein, JA Herbert, PS McNamara, CM Hedrich Clinical immunology 215, 108448	2020
Anakinra for severe forms of COVID-19: a cohort study T Huet, H Beaussier, O Voisin, S Jouveshomme, G Dauriat, I Lazareth, ... The Lancet Rheumatology 2 (7), e393-e400	2020
Cytokine storm intervention in the early stages of COVID-19 pneumonia X Sun, T Wang, D Cai, Z Hu, H Liao, L Zhi, H Wei, Z Zhang, Y Qiu, J Wang, ... Cytokine & growth factor reviews 53, 38-42	2020
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent A Mazzoni, L Salvati, L Maggi, M Capone, A Vanni, M Spinicci, ... The Journal of clinical investigation 130 (9), 4694-4703	2020
Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status TM Abd El-Aziz, JD Stockand Infection, Genetics and Evolution 83, 104327	2020
COVID-19: drug targets and potential treatments C Gil, T Ginex, I Maestro, V Nozal, L Barrado-Gil, MÁ Cuesta-Geijo, ... Journal of medicinal chemistry 63 (21), 12359-12386	2020
Current status of potential therapeutic candidates for the COVID-19 crisis J Zhang, B Xie, K Hashimoto Brain, behavior, and immunity 87, 59-73	2020
Targeting the NLRP3 inflammasome in severe COVID-19 TL Freeman, TH Swartz Frontiers in immunology, 1518	2020
SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression R Cecchini, AL Cecchini Medical hypotheses 143, 110102	2020
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19 Y Rodríguez, L Novelli, M Rojas, M De Santis, Y Acosta-Ampudia, ... Journal of autoimmunity 114, 102506	2020
Adoptive cellular therapies: the current landscape MW Rohaan, S Wilgenhof, JBAG Haanen Virchows Archiv 474, 449-461	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。